Cellectar Biosciences is a clinical stage biopharmaceutical company that engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The Company offers product candidates for the treatment of relapse or refractory multiple myeloma, B-cell malignancies and micrometastatic disease, as well as for the treatment of chemotherapy. It also provides PDCs for the selective detection of tumors and metastases, and intraoperative tumor and tumor margin illumination.

Type
Public
HQ
Madison, US
Founded
1996
Size (employees)
15 (est)
Cellectar Biosciences was founded in 1996 and is headquartered in Madison, US
Report incorrect company information

Cellectar Biosciences Office Locations

Cellectar Biosciences has an office in Madison
Madison, US (HQ)
3301 Agriculture Dr
Show all (1)
Report incorrect company information

Cellectar Biosciences Financials and Metrics

Cellectar Biosciences Financials

USD

Net income (Q1, 2017)

(2.9 m)

EBIT (Q1, 2017)

(2.8 m)

Market capitalization (5-Feb-2018)

15.3 m

Cash (3-Feb-2018)

11.2 m
Cellectar Biosciences's current market capitalization is $15.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

General and administrative expense

4.4 m3.7 m3.4 m4.7 m

R&D expense

6.9 m6 m5.2 m4.8 m

Operating expense total

11.3 m9.7 m8.6 m9.4 m

EBIT

(12.4 m)(9.9 m)(8.8 m)(9.4 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

General and administrative expense

959.9 k802.8 k943.4 k817.7 k834.9 k961.3 k1.4 m1.2 m955.4 k

R&D expense

1.4 m1.5 m1.6 m1.4 m1.2 m1 m965.2 k1.3 m1.9 m

Operating expense total

2.3 m2.3 m2.6 m2.2 m2 m2 m2.3 m2.5 m2.8 m

EBIT

(2.5 m)(2.3 m)(2.6 m)(2.3 m)(2.1 m)(2 m)(2.3 m)(2.5 m)(2.8 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.4 m9.4 m3.9 m11.4 m

Inventories

294.7 k220.6 k267.8 k693.6 k

Current Assets

2.8 m9.7 m4.2 m12.2 m

Goodwill

1.7 m1.7 m1.7 m1.7 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

1.6 m11.6 m7 m4.8 m2.5 m1.9 m7.9 m5.6 m11.2 m

Current Assets

2 m11.9 m7.3 m5 m3 m2.2 m8.1 m6.1 m12.2 m

Goodwill

1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m1.7 m

Total Assets

5.9 m15.7 m10.9 m8.6 m6.5 m5.6 m11.4 m9.3 m15.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(10.8 m)(8.1 m)(5.5 m)(6.2 m)

Depreciation and Amortization

424.8 k367.2 k362.5 k356.7 k

Inventories

48.1 k74.1 k(8.6 k)(464.4 k)

Short-term Borrowings

(617.5 k)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.1 m)(505.7 k)(2.3 m)(2.3 m)(1.9 m)824.6 k(2.1 m)(2.3 m)(2.9 m)
USDY, 2017

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information